Wendall Wierenga - 11 Jun 2025 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Reporting relationship: Director
Issuer ticker: CRNX
Reported as of: 11 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Jun 2025, 16:30:12 UTC
Prior SEC filing: 14 May 2025
Next SEC filing: 16 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Tobin Schilke, as attorney-in-fact

Key filing fact

Wendall Wierenga filed Form 4 for Crinetics Pharmaceuticals, Inc. (CRNX) on 13 Jun 2025.

Key facts

This page summarizes Wendall Wierenga's Form 4 filing for Crinetics Pharmaceuticals, Inc. (CRNX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 13 Jun 2025, 16:30.

Change

Previous filing in this sequence was filed on 14 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001235945 Primary reporting owner

WIERENGA WENDALL

Relationship: Director
Address: C/O CRINETICS PHARMACEUTICALS, INC., 6055 LUSK BOULEVARD, SAN DIEGO
Signature: /s/ Tobin Schilke, as attorney-in-fact
Signature date: 13 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CRNX transaction

Common Stock

Award

Transaction value: $0
Shares: +6,900
Change %: +6.3%
Price: $0.000000
Shares after: 116,146
Date: 11 Jun 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRNX transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +10,350
Change %
Price: $0.000000
Shares after: 10,350
Date: 11 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,350
Exercise price: $32.33
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.

Footnote F2

The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.